Compare Dollar General Corp. (DG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Illumina, Inc. — how do they compare? Dollar General Corp. trades at $119.27 (market cap $26.50B), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Dollar General Corp. and Illumina, Inc. are close in size by market cap, and Dollar General Corp. pays a 1.96% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DG | ILMN | |
|---|---|---|
Market Cap | $26.50B | $28.93B |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $194.33 |
52-Week Low | $95.94 | $91.00 |
Enterprise Value | $40.95B | $30.32B |
Dividend Yield | 1.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $123.44, up 3.8% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.00 exceeding expectations of $1.89. Revenue growth continues at $40.61B for 2025, while profit margins face pressure at 3.63%. Recent news highlights the company's back-to-school initiatives and margin expansion efforts.
The outlook remains positive with a $128.45 consensus price target representing 4% upside. Key opportunities include continued same-store sales growth and margin recovery, while risks involve consumer spending sensitivity and competitive pressures in discount retail. The technical setup suggests near-term resistance around $125-$128 levels.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
